Obesity drugmaker Novo Nordisk plunges as it cuts forecasts again

Novo Nordisk (NVO) shares declined as much as 17% after the obesity drugmaker cut its full-year 2025 sales and operating profit forecasts for the second time this year, citing lower growth expectations for its key drugs Wegovy and Ozempic in the U.S. and international markets. The revised sales growth outlook is now 8%-14% (down from 13%-21%) and operating profit growth 10%-16% (from 16%-24%), signaling increased competitive pressure from rivals like Eli Lilly and raising concerns about the company's future market penetration despite strong recent quarterly performance.

Analysis

Novo Nordisk is facing a significant crisis of confidence following its second downward revision of full-year 2025 guidance, which triggered a share price collapse of up to 17%. The company has materially lowered its sales growth forecast to 8%-14% from a prior 13%-21% and its operating profit growth estimate to 10%-16% from 16-24%. This revision is attributed to intensifying competitive pressure from U.S. rival Eli Lilly, leading to lower-than-expected growth for its flagship drugs Wegovy and Ozempic in the U.S. and disappointing international penetration for Wegovy. This forward-looking pessimism contrasts sharply with its recent strong performance, including an 18% year-over-year sales increase and a 40% operating profit jump in the second quarter. The situation is further complicated by leadership instability, with CEO Lars Fruergaard Jorgensen having been ousted in May. This development challenges the company's growth narrative and market dominance, which had previously made it Europe's most valuable company in 2024 before its valuation was more than halved.

Key Decisions for Investors

• Investors should exercise extreme caution with Novo Nordisk, as the sharp, repeated cuts to 2025 guidance and ongoing CEO transition signal a fundamental deterioration in its competitive position against Eli Lilly.
• The upcoming August 6 earnings report is a critical catalyst; monitor this for any further details on the magnitude of U.S. market share loss and management's strategy to stabilize the business.
• Consider the implications for the broader obesity drug market, as Novo Nordisk's guidance contraction directly signals a potential market share and pricing power advantage for its primary competitor, Eli Lilly.
• Despite the significant drop in share price, the fundamental questions raised about its long-term growth trajectory suggest that this may be a value trap rather than a buying opportunity until there is clear evidence of stabilization.